Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, bone diseases ...

People who repeatedly engage in a common bad habit could be at greater risk of more than 170 diseases, ranging from gangrene ...

Tumor necrosis factor inhibitor use in patients with IMIDs did not increase the risk of de novo heart failure or worsen existing heart failure.

This trauma-informed case study shows how deep emotional healing and nervous system regulation transformed a patient’s ...

Once touted as a potential powerhouse treatment for a variety of inflammatory conditions, Galapagos’ JAK inhibitor Jyseleca ...

I actually never wanted to be an obstetrician or gynaecologist. I always wanted to be a physician. I was training in diabetes ...

If you have brittle nails, swollen hands or unusually pale fingertips it may be more than just a damper to your manicure. It ...

Lymphedema, a condition of chronic swelling often after cancer treatment, affects 10 million Americans. Risk of lymphedema ...

Explore the potential of GLP-1 receptor agonists for rheumatoid arthritis. Learn about their safety, benefits, and what to consider before starting these medications.

Discover how Obexelimab's unique B-cell inhibition and pivotal Phase 3 IgG4 results could drive Zenas BioPharma, Inc.'s ...

In terms of consensus rating, Incyte is in the middle compared to its peers. Incyte has the highest revenue growth among its peers. Incyte also has the highest gross profit. However, Incyte has the ...